Research project to investigate the efficacy and safety of sotagliflozin in slowing the decline in kidney function in people with type 1 diabetes and moderate-to-severe diabetic nephropathy (SUGARNSALT).
Implication
The Montreal Clinical Research Institute (IRCM) is seeking participants for a research project under the supervision of Dr. Rémi Rabasa-Lhoret (IRCM).
This intervention study comprises a total of 19 visits, 18 of which will take place at the IRCM and one by telephone. The total duration of participation is 3 years and 4 months. Each visit will last a maximum of two hours.
- The main objective is to evaluate whether sotagliflozin can prevent the loss of kidney function that can occur with people living with type 1 diabetes.
- If you are eligible, you will be assigned to treatment or placebo for 3 years;
- Visits will involve blood tests, questionnaires and questions about your health;
- You will have the opportunity to update your knowledge of type 1 diabetes management and optimize your treatment;
- Financial compensation will be offered for your participation.
For the duration of the study, you will continue to use your diabetes treatment. Equipment for continuous blood glucose monitoring and ketone measurement will be provided for the duration of the project.
Inclusion criteria
- Have had type 1 diabetes for at least 8 years
- Be between 18 and 75 years of age
- Your doctor has informed you that you have kidney problems or the presence of albumin (protein) in your urine.
Information
Roxane St-Amand, research coordinator
Telephone: 514-987-5770
Roxane.st-amand@ircm.qc.ca
